276 related articles for article (PubMed ID: 34174987)
1. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
2. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS; Brown JR
Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
4. PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.
Hus I; Puła B; Robak T
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326722
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
6. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
[TBL] [Abstract][Full Text] [Related]
7. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
Vangapandu HV; Jain N; Gandhi V
Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
[TBL] [Abstract][Full Text] [Related]
8. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
10. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Shouse G; Danilova OV; Danilov AV
Curr Opin Oncol; 2022 Sep; 34(5):540-545. PubMed ID: 35855508
[TBL] [Abstract][Full Text] [Related]
11. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
12. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
Yin Y; Athanasiadis P; Karlsen L; Urban A; Xu H; Murali I; Fernandes SM; Arribas AJ; Hilli AK; Taskén K; Bertoni F; Mato AR; Normant E; Brown JR; Tjønnfjord GE; Aittokallio T; Skånland SS
Clin Cancer Res; 2022 Oct; 28(20):4444-4455. PubMed ID: 35998013
[TBL] [Abstract][Full Text] [Related]
13. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Nikolaenko L; Liu T; Danilov AV
Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
[No Abstract] [Full Text] [Related]
14. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
16. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
18. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
19. PI3-kinase inhibitors in chronic lymphocytic leukemia.
Chang JE; Kahl BS
Curr Hematol Malig Rep; 2014 Mar; 9(1):33-43. PubMed ID: 24390602
[TBL] [Abstract][Full Text] [Related]
20. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]